利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

55 条记录 (耗时 0.038 秒)

    Anti-obese compositions containing holoptelea integrifolia extracts
    41.
    发明授权
    Anti-obese compositions containing holoptelea integrifolia extracts 有权
    抗肥胖组合物含有全脑白藜芦醇提取物

    公开(公告)号：US09504722B2

    公开(公告)日：2016-11-29

    申请号：US12674113

    申请日：2007-08-20

    申请人： Ganga Raju Gokaraju ,  Rama Raju Gokaraju ,  Trimurtulu Golakoti ,  Krishanu Sengupta ,  Kiran Bhupatiraju

    发明人： Ganga Raju Gokaraju ,  Rama Raju Gokaraju ,  Trimurtulu Golakoti ,  Krishanu Sengupta ,  Kiran Bhupatiraju

    IPC分类号： A61K36/185

    CPC分类号： A61K36/185

    摘要： The present invention discloses the extracts of Holoptelea integrifolia or the purified fractions isolated there from and the dietary, nutraceutical and pharmaceutical compositions comprising the same or optionally in combination with one or more known anti-obesic agents useful for the purpose of inhibition, amelioration or prevention of adipogenesis and lipolysis involved diseases. The invention further discloses a method for treating or preventing obesity and adipogenesis and lipolysis involved diseases using the compositions containing the extracts of purified fractions of Holoptelea integrifolia.

    摘要翻译： 本发明公开了全息提取物或其中分离的纯化级分，以及包含与其一起使用或用于抑制，改善或预防的目的的一种或多种已知抗胆固醇剂的膳食，营养药物和药物组合物的饮食，营养药物和药物组合物 的脂肪生成和脂肪分解涉及疾病。 本发明进一步公开了一种治疗或预​​防肥胖和脂肪生成和脂肪分解的方法，该方法涉及使用含有Holoptelea integrifolia纯化部分提取物的组合物进行疾病。

    USES OF ANALOGS OF 3-O-ACETYL-11-KETO-BETA-BOSWELLIC ACID
    46.
    发明申请
    USES OF ANALOGS OF 3-O-ACETYL-11-KETO-BETA-BOSWELLIC ACID 审中-公开

    公开(公告)号：US20090318551A1

    公开(公告)日：2009-12-24

    申请号：US12549663

    申请日：2009-08-28

    申请人： Ganga Raju Gokaraju ,  Rama Raju Gokaraju ,  Venkata Subbaraju Gottumukkala ,  Trimurtulu Golakoti

    发明人： Ganga Raju Gokaraju ,  Rama Raju Gokaraju ,  Venkata Subbaraju Gottumukkala ,  Trimurtulu Golakoti

    IPC分类号： A61K31/215 ,  C07C61/29 ,  C07C69/757 ,  C07C255/47 ,  C07C69/78 ,  C07C229/02 ,  A61K31/19 ,  A61K31/235 ,  A61P35/00 ,  A61P29/00

    CPC分类号： C07J63/008

    摘要： This invention relates to novel AKBA analogs of the formula I given below: Where in R1, R2, R3, R4 and R5 in each of the said analogs are: 1. R1═OCHO, R2═H, R3═COOH, R4 & R5═O 2. R1═OCOCH2Cl, R2═H, R3═COOH, R4 & R5═O 3. R1=5′-O-methylgalloyloxy, R2═H, R3═COOH, R4 & R5═O 4. R1═OCOCH2CH2COOH, R2═H, R3═COOH, R4 & R5═O 5. R1=8′,9′-Dihydro-4′-hydroxycinnamoyloxy, R2═H, R3═COOH, R4 & R5═O 6. R1=4′-Hydroxycinnamoyloxy, R2═H, R3═COOH, R4 & R5═O 7. R1=3′,4′-Dimethoxycinnamoyloxy, R2═H, R3═COOH, R4 & R5′O 8. R1=3′,4′-Dihydroxy-5′-methoxycinnamoyloxy, R2═H, R3═COOH, R4 & R5═O 9. R1═OCOCH2NH(tert-BOC), R2═H, R3═COOCH3, R4 & R5═O 10. R1═OCOCH2NH2HCl, R2═H, R3═COOH, R4 & R5═O 11. R1═OCOCH(CH3)NH2HCl, R2═H, R3═COOH, R4 & R5═O 12. R1═H, R2═OH, R3═COOCH3, R4 & R5═O 13. R1═H, R2═Br, R3═COOCH3, R4 & R5═O 14. R1═CN, R2═H, R3═COOCH3, R4 & R5═O 15. R1═SH, R2═H, R3═COOCH3, R4 & R5═O 16. R1 & R2═N(OH), R3═COOCH3, R4 & R5═O 17. R1 & R2═H & OCOCH3 R3═H, R4 & R5═O 18. R1═OCOCH3, R2═H, R3═COOCH2CH2N(CH3)2, R4 & R5═O 19. R1═OCOCH3, R2═H R3═CONH2, R4 & R5═O 20. R1═OCOCH3, R2═H, R3═CONHNH2, R4 & R550 O 21. R1═OCOCH3, R2═H, R3═CONHCH2CH2NH2, R4 & R5═O 22. R1═OCOCH3, R2═H, R3═CONHCH2CH2OH, R4 & R5═O 23. R1═OCOCH3, R2═H, R3═CON(CH2CH2)2NH, R4 & R5═O 24. R1═OCOCH3, R2═H R3═NCO, R4 & R5═O 25. R1═OCOCH3, R2═H R3═NH2, R4 & R5═O 26. R1═OCOCH3, R2═H R3═CN, R4 & R5═O 27. R1═OH, R2═H R3═COOH, R4 & R5═OH & H These compounds exhibited 5-Lipoxigenase inhibitory properties and these compounds may be used in pharmaceutical compositions for therapeutic applications against a variety of inflammations and hypersensitivity-based human diseases including asthma, arthritis, bowel diseases such as ulcerative colitis and circulatory disorders such as shock and ischaemia. These compounds also inhibited the growth of Brine Shrimp in cultures, which may be considered as a positive indication for cytotoxicity and antitumor activity.

    Analogs of 3-O-acetyl-11-keto-β-boswellic acid
    47.
    发明授权
    Analogs of 3-O-acetyl-11-keto-β-boswellic acid 失效

    公开(公告)号：US07625947B2

    公开(公告)日：2009-12-01

    申请号：US10540257

    申请日：2004-06-18

    申请人： Ganga Raju Gokaraju ,  Rama Raju Gokaraju ,  Venkata Subbaraju Gottumukkala ,  Trimurtulu Golakoti

    发明人： Ganga Raju Gokaraju ,  Rama Raju Gokaraju ,  Venkata Subbaraju Gottumukkala ,  Trimurtulu Golakoti

    IPC分类号： A61K31/21 ,  A61K31/015 ,  C07C69/74

    CPC分类号： C07J63/008

    摘要： This invention relates to novel AKBA analogs of the formula I given below: Where in R1, R2, R3, R4 and R5 in each of the said analogs are: 1. R1═OCHO, R2═H, R3═COOH, R4 & R5═O 2. R1═OCOCH2Cl, R2═H, R3═COOH, R4 & R5═O 3. R1═5′-O-methylgalloyloxy, R2═H, R3═COOH, R4 & R5═O 4. R1═OCOCH2CH2COOH, R2═H, R3═COOH, R4 & R5═O 5. R1═8′,9′-Dihydro-4′-hydroxycinnamoyloxy, R2═H, R3═COOH, R4 & R5═O 6. R1═4′-Hydroxycinnamoyloxy, R2═H, R3═COOH, R4 & R5═O 7. R1═3′,4′-Dimethoxycinnamoyloxy, R2═H, R3═COOH, R4 & R5═O 8. R1═3′,4′-Dihydroxy-5′-methoxycinnamoyloxy, R2═H, R3═COOH, R4 & R5═O 9. R1═OCOCH2NH(tert-BOC), R2═H, R3═COOCH3, R4 & R5═O 10. R1═OCOCH2NH2HCl, R2═H, R3—COOH, R4 & R5═O 11. R1═OCOCH(CH3)NH2HCl, R2═H, R3═COOH, R4 & R5═O 12. R1═H, R2═OH, R3═COOCH3, R4 & R5═O 13. R1═H, R2═Br, R3 COOCH3, R4 & R5═O 14. R1═CN, R2═H, R3═COOCH3, R4 & R5═O 15. R1═SH, R2═H, R3═COOCH3, R4& R5═O 16. R1 & R2═N(OH), R3═COOCH3, R4 & R5═O 17. R1 & R2═H & OCOCH3 R3═H, R4 & R5═O 18. R1═OCOCH3, R2═H R3═COOCH2CH2N(CH3)2, R4 & R5═O 19. R1═OCOCH3, R2═H R3═CONH2, R4 & R5═O 20. R1═OCOCH3, R2═H, R3═CONHNH2, R4 & R5═O 21. R1═OCOCH3, R2═H, R3═CONHCH2CH2NH2, R4 & R5═O 22. R1═OCOCH3, R2═H, R3═CONHCH2CH2OH, R4 & R5═O 23. R1═OCOCH3, R2═H, R3═CON(CH2CH2)2NH, R4 & R5═O 24. R1═OCOCH3, R2═H R3═NCO, R4 & R5═O 25. R1═OCOCH3, R2═H R3═NH2, R4 & R5═O 26. R1═OCOCH3, R2═H R3═CN, R4 & R5═O 27. R1═OH, R2═H R3═COOH, R4 & R5═OH & H These compounds exhibited 5-Lipoxigenase inhibitory properties and these compounds may be used in pharmaceutical compositions for therapeutic applications against a variety of inflammations and hypersensitivity-based human diseases including asthma, arthritis, bowel diseases such as ulcerative colitis and circulatory disorders such as shock and ischaemia. These compounds also inhibited the growth of Brine Shrimp in cultures, which may be considered as a positive indication for cytotoxicity and antitumor activity.

    Process for producing enriched fractions containing up to 100% of bacopasaponins from the plant materials of bacopa species
    48.
    发明授权
    Process for producing enriched fractions containing up to 100% of bacopasaponins from the plant materials of bacopa species 有权
    从棒杆菌属植物材料生产含有高达100％的杆菌皂苷的富集级分的方法

    公开(公告)号：US08541381B2

    公开(公告)日：2013-09-24

    申请号：US11813778

    申请日：2005-05-03

    申请人： Raju Gokaraju Ganga ,  Raju Gokaraju Rama ,  Subbaraju Gottumukkala Venkata ,  Trimurtulu Golakoti ,  Sivaramakrishna Chillara

    发明人： Raju Gokaraju Ganga ,  Raju Gokaraju Rama ,  Subbaraju Gottumukkala Venkata ,  Trimurtulu Golakoti ,  Sivaramakrishna Chillara

    IPC分类号： A61K31/70 ,  A61K31/7028 ,  C07H17/00

    CPC分类号： A61K36/80

    摘要： This invention describes a process for producing a fraction enriched with jujubogenin and psudojujubogenin lycosides from Bacopa species, wherein the total Bacopa saponin concentration is up to 100% when estimated by HPLC method of analysis. The present invention also describes the processes for the enrichment of new compositions and individual saponin compounds from Bacopa monnieri to more than 95% purity. It further describes an analytical HPLC method for the estimation of total Bacopa saponin fraction and its use in therapeutic applications. This invention also includes two Bacopa saponin 3-O-[β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyl] jujubogenin and 3-O-[β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyl] pseudojujubogenin herein referred to as bacopaside N1 of general formula (1) and bacopaside N2 of general formula (2) respectively.

    摘要翻译： 本发明描述了从Bacopa物种生产富集jujubogenin和psudojujubogenin lycosides的级分的方法，其中当通过HPLC分析方法估计时，总Bacopa皂苷浓度高达100％。 本发明还描述了从Bacopa monnieri中将新组合物和单独皂苷化合物富集至95％以上纯度的方法。 它进一步描述了用于估计总Bacopa皂角苷级分的分析型HPLC方法及其在治疗应用中的用途。 本发明还包括两种Bacopa皂角苷3-O-β-D-吡喃葡萄糖基 - （1-> 3）-β-D-吡喃葡萄糖基] jujubogenin和3-O- [β-D-吡喃葡萄糖基 - （1-> 3） β-D-吡喃葡萄糖基]假胡椒素原，本文中分别称为通式（1）的杆菌肽N1和通式（2）的杆菌肽N2。

    Process For Producing Enriched Fractions Containing Up To 100% Of Bacopasaponins From The Plant Materials Of Bacopa Species
    49.
    发明申请
    Process For Producing Enriched Fractions Containing Up To 100% Of Bacopasaponins From The Plant Materials Of Bacopa Species 有权
    从Bacopa物种的植物材料中生产含有高达100％的Bacopasaponins的富含级分的方法

    公开(公告)号：US20080132455A1

    公开(公告)日：2008-06-05

    申请号：US11813778

    申请日：2005-05-03

    申请人： Raju Gokaraju Ganga ,  Raju Gokaraju Rama ,  Subbaraju Gottumukala Venkata ,  Trimurtulu Golakoti ,  Sivaramakrishna Chillara

    发明人： Raju Gokaraju Ganga ,  Raju Gokaraju Rama ,  Subbaraju Gottumukala Venkata ,  Trimurtulu Golakoti ,  Sivaramakrishna Chillara

    IPC分类号： A61K31/70 ,  A61P25/28 ,  C07G3/00

    CPC分类号： A61K36/80

    摘要： This invention describes a process for producing a fraction enriched with jujubogenin and psudojujubogenin lycosides from Bacopa species, wherein the total Bacopa saponin concentration is up to 100% when estimated by HPLC method of analysis. The present invention also describes the processes for the enrichment of new compositions and individual saponin compounds from Bacopa munnieri to more than 95% purity. It further describes an analytical HPLC method for the estimation of total Bacopa saponin fraction and its use in therapeutic applications. This invention also includes two Bacopa saponin 3-O-[β-D-glucopyranosyl-(1 3)-β-D-glucopyranosyl] jujubogenin and 3-O-[β-D-glucopyranosyl-(1 3)-β-D-glucopyranosyl] pseudojujubogenin herein referred to as bacopaside N1 of general formula (1) and bacopaside N2 of general formula (2) respectively.

    摘要翻译： 本发明描述了从Bacopa物种生产富集jujubogenin和psudojujubogenin lycosides的级分的方法，其中当通过HPLC分析方法估计时，总Bacopa皂苷浓度高达100％。 本发明还描述了从Bacopa munnieri中将新组合物和单独皂苷化合物富集至纯度达95％以上的方法。 它进一步描述了用于估计总Bacopa皂角苷级分的分析型HPLC方法及其在治疗应用中的用途。 本发明还包括两种Bacopa皂角苷3-O- [β-D-吡喃葡萄糖基 - （1,3）-β-D-吡喃葡萄糖基] jujubogenin和3-O- [β-D-吡喃葡萄糖基 - （13）-β-D - 吡喃葡萄糖基]假胡椒素原，本文称为通式（1）的杆菌肽N1和通式（2）的杆菌肽N2。